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Objective. To estimate medium-term success after a technique for ultrasound-guided sclerotherapy for superficial chronic
venous disease.
Design. A prospective study in a single unit with ultrasound surveillance after treatment.
Materials. Results after 1189 treatment sessions for 807 venous saphenous veins and related tributaries or non-saphenous
tributaries in 489 patients.
Methods. Univariate life table analysis determined primary and secondary success rates. Multivariate Cox regression
analysis detected covariates that affected outcome.
Results. Primary and secondary success rates at 36 months for all veins were 52.4% (95%CI 46e58%) and 76.8%
(95%CI 71e82%). Cox regression analysis for primary success for all veins showed significantly worse results for saphe-
nous veins compared to tributaries (HR 3.72 e 95%CI 1.9 to 7.3). Cox regression for all saphenous veins showed inde-
pendently worse results for patients less than 40 years age (HR 2.16 e 95%CI 1.27e3.66), small compared to great
saphenous veins (HR 1.58 e 95%CI 1.11e2.24), veins greater than 6mm diameter compared to smaller veins (HR
2.22 e 95%CI 1.40e3.50), liquid compared to foam sclerotherapy (HR 2.20 e 95%CI 1.28e3.78), lower volumes of scle-
rosant compared to volumes greater than 12 ml (HR 0.51 e 95%CI 0.33e0.81) and highly diluted compared to concen-
trated sclerosant (HR 2.05 e 95%CI 1.21e3.46) with worse results using highly diluted or undiluted 3% sclerosant
compared to a 1.5% concentration. There were no significant differences for primary success for saphenous veins for
date of procedure, sex, side, primary or recurrent varicose veins, or commercial type of sclerosant.
Conclusions. Ultrasound-guided sclerotherapy gives satisfactory results if it is accepted that treatment may need to be
repeated to achieve secondary success. Results provide a basis for further research to explore factors that might affect out-
come. Younger patients with larger diameter saphenous veins may warrant alternative forms of treatment, particularly for
small saphenous reflux.
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Many phlebologists now favour ultrasound-guided
sclerotherapy to treat varicose veins but there are few
published reports of the outcome. Earlier studies have
presented results for liquid and foam sclerotherapy.1e7
Various techniques are advocated but there is little
objective evidence that any one has an advantage
over others in clinical practice. This paper presents a
prospective observational study of a technique for
ultrasound-guided sclerotherapy in a single unit with
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assessed by life table analysis to allow assessment of
medium-term success rates and Cox regression anal-
ysis for the influence of covariates that might influ-
ence outcome. The aim was to determine whether
results suggested ways to improve outcome and in-
dicate directions for future research to evaluate best
patient selection and treatment methods.
Materials and Methods
Patients and veins treated
This was a prospective study to determine outcome
assessed by ultrasound surveillance. Only patientsrved.
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ultrasound-guided sclerotherapy were analysed. Pa-
tients treated with follow-up ultrasound-guided scle-
rotherapy after endovenous laser therapy were not
included. The treatment period was from early 1999
to mid 2005. There were 1189 treatment sessions for
807 saphenous veins and related tributaries as well
as non-saphenous varices in 677 lower limbs of 489
patients. Of the 1189 treatment sessions, success was
achieved with one sclerotherapy session in 767
(65%), two sessions in 153 (26%) and three or more
sessions in 34 (9%), an average of 1.49 sessions per ve-
nous system treated. Of the 807 saphenous veins and
related tributaries as well as non-saphenous varices
initially successfully treated, subsequent failure due
to development of reflux in the treated veins as shown
by ultrasound resulted in the patient returning for
a second series of treatments for 113 (14%) and for
a third series in 15 and fourth for 5 (2%). The authors
decided not to record clinical success or failure or
other indicators of outcome such as quality of life or
cost-benefit analysis.
The patients’ ages ranged from 19 to 92 (median 53)
years with 401 women (82%) and 88 men. The clinical
CEAP category was determined for each limb.8 For
limbs with saphenous reflux, the clinical CEAP cate-
gory was C2-3 in 569 (90%) and C4-6 in 62 limbs
(C4-39, C5-21, C6-2). Primary varicose veins were
present in 516 limbs (82%) and recurrent varicose
veins after previous saphenous vein surgery in 115
limbs.
Reflux was present in the great saphenous vein or
tributaries in 454 limbs (56%) including 5 where reflux
was present in the anterior accessory saphenous vein
rather than the great saphenous vein. The small
saphenous territory vas involved in 177 limbs (22%)
including 8 with involvement of the thigh extension
or vein of Giacomini, and tributaries alone without re-
flux in either saphenous system in 176 limbs (22%).
There were 60 limbs where both the great and small
saphenous veins were treated.
Pre-operative ultrasound assessment
All patients were studied before the procedure by
qualified vascular sonographers in the unit as previ-
ously described.9 Scans were performed with the pa-
tient standing and the limb relaxed. Reflux was
defined as retrograde flow lasting for greater than
0.5 seconds in the affected vein. Reflux at the sapheno-
femoral junction was elicited with the Valsalva ma-
noeuvre and at the saphenopopliteal junction by
a calf compression-release manoeuvre. The scanassessed all deep, superficial and perforating veins.
The diameter of incompetent saphenous trunks was
measured.
Techniques for treatment
The sclerosant drugs used and their preparation var-
ied from patient to patient according to the size and
extent of the varicose veins and the attitude of the
treating surgeon (KM). This provides an opportunity
to compare success rates for different treatment tech-
niques. The drug used was either sodium tetradecyl
sulphate or polidocanol and these were not used in
combination in any patient. No more than 4 ml of
3% sodium tetradecyl sulphate or 2 mg/kg of 3%
polidocanol was used at any one treatment session
as recommended by the Australian Therapeutic
Goods Administration (TGA). In the first year, liquid
sclerosant at a 3% concentration was used for 98 treat-
ment sessions. From early 2000, foamed sclerosant
was used for all procedures. Sclerosant foam was pre-
pared from 0.6e3% sclerosant liquid, using saline di-
lution, to provide greater volumes of foam for more
extensive varicose disease. Foam was made by a mod-
ification of the Tessari method10 with two parts of
sclerosant combined with three parts of air mixed be-
tween two syringes connected by a two-way tap with
a 5 micron filter in the system. Initially, no limit was
placed on the maximum volume of foam given at
one session although it is now restricted to no more
than 20 ml of foam. The volume injected per session
ranged from 3e40 ml foam (median 5 ml).
Injections were given as far distally and away from
connections between superficial to deep veins as was
possible while patients lay supine. The aim was to
find a ‘‘strategic vein’’ that appeared from the preop-
erative scan to provide the best avenue for foam to fill
the full length of the venous system to be treated. If
scanning showed that sclerosant had not filled the
veins then it was gently massaged along their length
until it appeared at the appropriate saphenous junc-
tion. Usually, only one injection was required to fill
the vein. Further injections at the proximal limit were
performed if necessary. The sonographer followed the
passage of foam and applied pressure to saphenous
junctions or large perforators with the probe as foam
approached.
The vein was usually viewed in the longitudinal
axis and injection made with a 5 ml or 10 ml syringe
and 1.5-inch-long 25-gauge needle. Injections were
given into a prominent tributary where this was tech-
nically easier in 223 procedures (24%). Tributaries
were injected either with or without ultrasoundEur J Vasc Endovasc Surg Vol 33, January 2007
118 K. A. Myers et al.guidance. Foam was often seen to pass from one sa-
phenous system to the other through communicating
veins.
Following completion of injections, compression
was applied with a two layer bandage if there were
prominent superficial tributaries, or a class II thigh-
length stocking if superficial veins were not promi-
nent. Each patient was then immediately mobilised
and asked to walk for about 15 minutes. Initial com-
pression was maintained for three days and then
changed to a compression stocking in all patients,
worn just through the day and removed at night
and for the morning shower. Compression was main-
tained for two to three weeks depending on the de-
gree of reaction in the superficial veins. Ambulation
was encouraged during the first 2 weeks.
Post-operative ultrasound surveillance
All patients were assessed by an ultrasound scan at
3e5 days after every treatment session to assess the
effect of treatment, to detect residual patent veins re-
quiring further treatment, and to detect deep vein
thrombosis. Ultrasound scans and clinical review
were then repeated at 6 weeks, 6-monthly for two
years and then annually to determine whether treated
veins were absent, occluded, patent or refluxing.
Reflux in non-treated veins was also recorded.
Statistical analysis
Data were entered prospectively into an Excel spread-
sheet and statistical analysis was performed with
Stata software. Primary success was defined as per-
sistent occlusion or absence of reflux in the treated
venous segment. Secondary success was defined as
persistent occlusion or absence of reflux in the treated
venous segment after further ultrasound-guided scle-
rotherapy for primary failure. The time for com-
mencement of surveillance was the date at which
the last treatment session was performed that
achieved occlusion of the treated venous system.
The time to failure was the interval at which reflux
was noted on the follow-up scan at the next scheduled
appointment. If the patient had missed a scheduled
appointment then the time to failure was dated back
to that missed appointment.
Univariate life table analysis using Kaplan-Meier
curves was performed for primary and secondary
success for all veins and for tributaries without saphe-
nous reflux, great saphenous reflux with or without
tributaries, and small saphenous reflux with or with-
out involvement of the thigh extension or tributaries.Eur J Vasc Endovasc Surg Vol 33, January 2007Multivariate Cox regression analysis was used to esti-
mate hazard ratios for covariates that might affect out-
come for all veins and for all saphenous veins. The
covariates studied were age and sex, right or left
side, date of procedure, primary or recurrent varicose
veins, vein treated, representative diameter of the
vein, technique of injection into tributaries or the
saphenous trunk, use of foam or liquid, sodium tetra-
decyl sulphate or polidocanol, concentration of sclero-
sant, and volume of liquid or foam infused. Specific
covariates for great saphenous veins were the extent
of involved vein above and below knee and the source
of reflux from the deep system through the sapheno-
femoral junction or other sites such as low abdominal
or pelvic veins or perforators. For covariates with
continuous rather than categorical data, an arbitrary
point was taken to separate approximately equal
subgroups.
To avoid linearity assumptions, we categorized con-
tinuous covariates. We selected categories based on
quartiles of the variable’s distribution, independent of
its association with the outcome variable. We used a
likelihood-ratio c2 test to assess the contribution of
each predictor variable in a final model. The unit of
analysis for Cox proportional hazard regression was
the vein. We used the Huber/White sandwich estima-
tor of variance to accommodate clustering of veins
within the same patient. Each vein inherited the
higher-level characteristics of its ‘parent’ limb and
patient within the regression model.
Results
Primary and secondary success rates
Primary and secondary success rates at three years for
all veins were 52.4% (95%CI 46 to 58%) and 76.8%
(95%CI 71 to 82%) respectively (Fig. 1).
Covariates affecting primary success rates
All veins
Cox regression analysis for all veins treated showed
significantly worse primary success rates for saphe-
nous veins compared to tributaries alone (HR 3.72 e
95%CI 1.9 to 7.3). Primary success rates at three years
from life table analysis were 83.4% (95%CI 69 to 91%)
for tributaries, 53.1% (95%CI 45 to 60%) for great sa-
phenous veins, and 36.1% (95%CI 25 to 48%) for small
saphenous veins (Fig. 2).
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Cox regression analysis for all saphenous veins and
related tributaries showed worse primary success
rates for patients less than 40 years age (HR 2.16 e
95%CI 1.27e3.66 compared to patients 50e59 years).
In relation to veins, there were worse results for small
compared to great saphenous veins (HR 1.58 e 95%CI
1.11e2.24) and veins >6 mm diameter (HR 2.22 e
95%CI 1.40e3.50 compared to veins <5 mm diame-
ter). For the technique of injection, there were worse
results for liquid compared to foam sclerotherapy
(HR 2.20 e 95%CI 1.28e3.78), smaller volumes of scle-
rosant compared to volumes >12 ml (HR 0.51 e
95%CI 0.33e0.81 and highly diluted compared to
more concentrated sclerosant (HR 2.05 e 95%CI
1.21e3.46), (Table 1). In addition, hazard ratios
suggest better results for patients older than 70
years compared to patients aged 50e59 years (HR
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Fig. 2. Kaplan-Meier curves showing primary success rates
for tributaries alone, great saphenous systems and small
saphenous systems after treatment by ultrasound-guided
sclerotherapy.
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Fig. 1. Kaplan-Meier curves showing primary and second-
ary success rates with 95% confidence intervals for all veins
treated by ultrasound-guided sclerotherapy.0.63 e 95%CI 0.35e1.14), and CEAP category C4-6
compared to C2-3 (HR 1.57 e 95%CI 0.91e2.73). Other
covariates studied showed little influence on
outcome.
Subsequent arbitrary subdivision of success rates
for each of the sclerosant concentrations used showed
best results for a 1.5% solution compared to either
stronger or weaker concentrations (Fig. 3).
Postoperative complications
Deep vein thrombosis was detected by the routine
early postoperative scan after 16 procedures. There
were 9 occlusive posterior tibial vein thromboses
and 7 partially occlusive femoropopliteal thromboses
which represented 1.8% and 1.4% of the 489 patients
respectively. All were asymptomatic and resolved
with a short period of treatment with subcutaneous
low molecular weight heparin therapy. Follow-up
scans showed persisting reflux after recanalisation in
the posterior tibial segment in 5 limbs. All deep vein
thromboses followed use of foam and the volume
infused ranged from 5e35 ml (median 14 ml). No
clinical episodes of pulmonary embolism or other
cardiovascular complications were observed. Three
Table 1. Cox regression analysis of covariates studied for outcome
of ultrasound-guided sclerotherapy for saphenous veins
Variable Level N Hazard
Ratio
95% Conf.
Interval
P-value
Age <40yr 93 2.16 1.27 3.66 0.004
40e49yr 121 1.11 0.69 1.78 0.661
50e59yr* 208 1
60e69yr 118 1.22 0.79 1.89 0.362
70þyr 87 0.63 0.35 1.14 0.127
Sex Male 112 1.31 0.88 1.94 0.181
Female* 515 1
Side Right 313 1.19 0.89 1.57 0.239
Left* 314 1
Vein GSV* 453 1
SSV 174 1.58 1.11 2.24 0.011
CEAP C2/3* 565 1
C4/6 62 1.57 0.91 2.73 0.106
Preparation Foam* 557 1
Liquid 70 2.20 1.28 3.78 0.005
Dilution 0.6% 213 2.05 1.21 3.46 0.007
0.8e1.2% 122 1.38 0.78 2.45 0.268
>1.2%* 292 1
Volume <6 ml* 320 1
6e12 ml 158 1.04 0.71 1.52 0.848
>12 ml 149 0.51 0.33 0.81 0.004
Diameter <5 mm* 211 1
5 mm 152 1.27 0.79 2.03 0.325
6 mm 152 2.07 1.35 3.18 0.001
>6 mm 112 2.22 1.4 3.5 0.001
*Baseline category.Eur J Vasc Endovasc Surg Vol 33, January 2007
120 K. A. Myers et al.patients with a prior history of migraine headaches
developed visual aura during mobilisation after injec-
tion, all typical of previous symptoms, and all settled
within 20 minutes without headache or residual neu-
rological deficit. No other neurological symptoms
were observed. No other complications occurred.
Discussion
Ultrasound-guided sclerotherapy has gained great
popularity but there has been little objective clinical
appraisal of its results compared to other forms of
treatment, or factors that might influence outcome to
help select the most suitable patients.
Ultrasound surveillance provides the most strin-
gent test for success after any treatment for varicose
veins. It is also important to determine factors such
as clinical recurrence rates, patient satisfaction, qual-
ity of life and cost-effectiveness but these were not as-
sessed in this study. Ultrasound surveillance has been
used by van Rij and colleagues to determine outcome
after surgery, with success at three years in 79% of
limbs after great saphenous surgery and 49% of limbs
after small saphenous surgery.11 It has also been used
to determine success after radiofrequency closure for
great saphenous reflux12 and after endovenous laser
therapy for great and small saphenous reflux.13,14
However, there are few studies after ultrasound-
guided sclerotherapy. Kanter and Thibault reported
cumulative success of 76% at two years from an early
experience with liquid sclerosant3 while Belcaro and
colleagues showed 56% success at 10 years with foam
sclerotherapy.4
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Fig. 3. A graph showing the rate of primary failure, per
person-year, by concentration of sclerosant. The vertical
bars are 95% confidence intervals.Eur J Vasc Endovasc Surg Vol 33, January 2007In our study, most veins were obliterated with one
treatment session, in agreement with the experience of
Cabrera and colleagues.5,6 Primary success rates at
three years for saphenous veins determined by ultra-
sound are little better than 50% so that patients should
be warned that repeat treatment may be required at
some time in the future. The improved secondary suc-
cess rates might have been higher if all patients had
agreed to repeat treatment.
We could find no compelling clinical evidence to
favour any technique for preparation of the sclerosant
or its administration. Accordingly, we chose to use
various techniques in an attempt to select the best
methods. In Australia, the regulatory authority (the
Therapeutic Goods Administration) recommend that
no more than 4 ml of a 3% solution of sodium tetra-
decyl sulphate and 2 mg/kg of polidocanol should
be used at any one treatment session and this recom-
mendation was followed. The most commonly used
technique in Australia is to administer a 3% solution
of either sclerosant but we elected to dilute this to in-
crease the volume of foam in many patients. It was
considered that inclusion of a 5 micron filter in the
system increased foam stability.
When saphenous veins were considered in this
study, no significant independent influence on out-
come was demonstrated for date of procedure, sex,
side, primary or recurrent varicose veins, or commer-
cial type of sclerosant. Treatment was more likely to
be effective for older patients, great saphenous com-
pared to small saphenous veins, foamed sclerosant
rather than liquid independent of experience, 1.5%
sclerosant rather than more diluted or undiluted 3%
sclerosant, larger volumes of sclerosant, and smaller
compared to larger diameter veins. There were other
covariates where hazard ratios suggested better out-
come such as clinical C2 rather than C4-6. Others
have reported better outcome for small compared to
large diameter veins9,10 although satisfactory results
for large veins have also been reported.5,15 Other find-
ings are not necessarily intuitive so that their main
value is to point to fields for further research. For ex-
ample, it is not clear why outcome should be influ-
enced by age or concentration of sclerosant, while we
find it difficult to explain the marked difference in re-
sults between the great and small saphenous veins.
The use of foam compared to liquid is strongly sup-
ported in the contemporary literature.5,16,17 Concerns
have been expressed regarding the maximum volume
of foam that should be used at one session and a Euro-
pean consensus group and a German national group
have established guidelines18,19 but these have not
yet been subjected to scientific analysis. No conclusive
evidence is available that larger volumes are
121Ultrasound-guided Sclerotherapy for Varicose Veinsassociated with any increased risk to the patient other
than the possible slightly increased likelihood of deep
vein thrombosis observed in the present study.
The only complication observed in this study was
deep vein thrombosis which occurred in 3.2% of pa-
tients. This is somewhat higher than reported in other
studies20 but this may reflect an aggressive policy to
scan the deep veins within a few days after treatment
for every sessionwhich detected asymptomatic throm-
bosis. This rate is similar to that described with ultra-
sound evaluation after surgery for varicose veins.21
Neurological complications have been reported22,23
but were not observed in this series.
The findings from this study support the use of
ultrasound-guided sclerotherapy for varicose disease
with or without saphenous reflux provided patients
are warned of the possible need for repeat treatment
to achieve secondary success. Results are not as good
for large diameter veins or disease in younger patients,
particularly for the small saphenous vein. The most ef-
fective concentration of sclerosant was 1.5%. Patients
should be of the risk of deep vein thrombosis.
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